Rapport Therapeutics, Inc. (RAPP)

Rapport Therapeutics' stock has experienced significant movement over the past six months. The stock price increased by 274.93% over the last 12 months, with a year-to-date return of 31.61% and an 18.52% increase in the past month as of May 8, 2026. Key events impacting the stock include the Q1 2026 earnings report where the company reported its first collaboration revenue of $20.0 million, significantly beating revenue expectations, driven by the licensing deal with Tenacia Biotechnology. Positive Phase 2a follow-up data for RAP-219 in focal onset seizures demonstrated sustained seizure reduction and a longer half-life. Insider selling by Third Rock Ventures tempered sentiment despite positive news. Raymond James initiated coverage with a 'Strong Buy' rating, contributing to positive investor sentiment. A $269.4 million follow-on equity offering completed in 2025 bolstered the company's cash reserves, providing funding for late-stage trials.

There is no indication of demand seasonality for Rapport Therapeutics' products or services in the provided information, as demand is driven by medical need and the progression of clinical trials and regulatory approvals.

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule precision medicines for patients with central nervous system (CNS) disorders. The company operates within the Healthcare sector, specifically in the Biotechnology & Medical Research industry, with a primary focus on Drug Discovery. The company's approach is based on understanding how receptor-associated proteins (RAPs) regulate receptor expression and function, allowing for the development of CNS drugs that are more specific to receptor variants and neuroanatomical regions. Its major product candidate, RAP-219, is being developed for the treatment of focal onset epilepsy, primary generalized tonic-clonic seizures, peripheral neuropathic pain, and bipolar disorder. The company also has Nicotinic Acetylcholine Receptor (nAChR) programs, including modulators of α6 nAChRs for chronic pain and migraine, and modulators of α9α10 nAChRs for hearing and vestibular disorders.

Rapport Therapeutics is headquartered in Boston, Massachusetts, United States. The company has expanded its market reach through a strategic collaboration and license agreement with Tenacia Biotechnology (Hong Kong) Co., Ltd. for the development and commercialization of RAP-219 in Greater China.

Rapport Therapeutics' brand reputation has been primarily influenced by its clinical development progress and financial performance. Positive Phase 2a follow-up data for RAP-219 in focal onset seizures, demonstrating sustained seizure reduction and a longer half-life, has likely enhanced its scientific and clinical reputation. The successful Q1 2026 earnings report, driven by collaboration revenue from a licensing deal in Greater China, has positively impacted its financial standing and market perception.

Rapport Therapeutics has significant institutional ownership, accounting for 99.35% of shares, while individuals hold 4.54%. Major institutional owners include Fmr Llc, Arch Venture Corp / Arch Venture Partners XII LLC / Arch Venture Management LLC, Capital International Investors, Goldman Sachs Group Inc, BlackRock, Inc., Sofinnova Investments, Inc., Vanguard Group Inc, Johnson & Johnson, Baker Bros. Advisors Lp, Vestal Point Capital, LP, Polar Capital Holdings Plc, State Street Corp., Swedbank AB, Manulife Financial Corp., Schweizerische Nationalbank, SEI Investments Co., and Cormorant Asset Management LP. Third Rock Ventures V LP is the largest individual Rapport Therapeutics shareholder, owning 7.68 million shares, representing 16.07% of the company.